9:49 AM ET
Earnings Call
▶ Call
Viridian Therapeutics Earnings Call: Key Takeaways
Viridian Therapeutics reported a strong LUMVO launch with $24.7 million in revenue, treating over 100 patients in its first quarter, while maintaining a robust $955 million cash position for future pipeline development.
- Call
- Nov 4, 2026, 8:00 AM ET